MNG1225
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.655
- INTERFERON_GAMMA_RESPONSE+0.640
- ALLOGRAFT_REJECTION+0.579
- IL6_JAK_STAT3_SIGNALING+0.484
- INFLAMMATORY_RESPONSE+0.467
- G2M_CHECKPOINT+0.444
- PROTEIN_SECRETION+0.430
- E2F_TARGETS+0.419
- PI3K_AKT_MTOR_SIGNALING+0.374
- MITOTIC_SPINDLE+0.342
Top 10 suppressed
- MYOGENESIS-0.337
- WNT_BETA_CATENIN_SIGNALING-0.252
- ESTROGEN_RESPONSE_EARLY-0.233
- PANCREAS_BETA_CELLS-0.223
- APICAL_JUNCTION-0.220
- ESTROGEN_RESPONSE_LATE-0.219
- KRAS_SIGNALING_DN-0.199
- HYPOXIA-0.162
- SPERMATOGENESIS-0.155
- COAGULATION-0.143
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BT-A20O-01A-21R-A14Y-07 | — | — | 0.889 |
| 2 | TCGA-55-8205-01A-11R-2241-07 | — | cohortA1 | 0.867 |
| 3 | aefb974b-c7d9-47f0-8f18-9346c087ea64 | — | — | 0.860 |
| 4 | SRR934953 | — | — | 0.860 |
| 5 | BS_XF0ZX2B3 | EPN | Supratentorial EPN | 0.858 |
| 6 | SJEPD030292_D1.RNA-Seq | EPN | Supratentorial EPN | 0.857 |
| 7 | MNG766 | — | — | 0.854 |
| 8 | SRR5088918 | — | — | 0.842 |
| 9 | SRR15030888 | — | — | 0.836 |
| 10 | 4c67fdfb-4b74-46c4-9021-0b5317207db5 | — | — | 0.836 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.655 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.640 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.579 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.484 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.467 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.444 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.430 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.419 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.374 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.342 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.322 | Inavolisib | — uncovered |
| COMPLEMENT | 0.321 | Inavolisib | — uncovered |
| APOPTOSIS | 0.267 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.264 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.218 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.218 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.211 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.195 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.192 | Inavolisib | — uncovered |